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Abstract
The CCL2 CCR2 axis is likely to contributes to the development and progression of cancer diseases by two major
mechanisms; autocrine effect of CCL2 as a survival/growth factor for CCR2+ cancer cells and, the attraction of CCR2+
CX3CR1+tumor associated macrophages that in the absence of CCR2 hardly migrate. Thus far no in vivo system has been set
up to differentiate the selective contribution of each of these features to cancer development. Here we employed a chimera
animal model in which all non-malignant cells are CCR22/2, but all cancer cells are CCR2+, combined with an adoptive
transfer system of bone marrow (BM) CX3CR1+ cells from CCR2+ mice harboring a targeted replacement of the CX3CR1gene
by an enhanced green fluorescent protein (EGFP) reporter gene (cx3cr1
gfp), together with the CD45.1 congene. Using this
system we dissected the selective contribution of CX3CR1+CCR2+ cells, which comprise only about 7% of CD11b+ BM cells,
to tumor development and angiogenesis. Showing that aside for their direct pro-angiogenic effect they are essential for the
recruitment of other CD11b+ cells to the tumor site. We further show that the administration of CCR2-Ig, that selectively and
specifically neutralize CCL2, to mice in which CCR2 is expressed only on tumor cells, further suppressed tumor development,
implicating for the key role of this chemokine supporting tumor survival in an autocrine manner. This further emphasizes
the important role of CCL2 as a target for therapy of cancer diseases.
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Introduction
Chemokines are small (,8–14 kDa), structurally related
proteins that regulate cell trafficking via interactions with a subset
of seven-transmembrane, G protein-coupled receptors [1,2,3,4].
Cancer cells express different chemokine receptors and also
produce their ligands. One of them is CCR2 and its major ligand
CCL2 (MCP-1). CCL2 is a major inflammatory chemokine that
also participates in the regulation of cancer disease. CCL2 and
other CCR2 ligands are highly expressed by various tumors, such
as melanoma, breast cancer, ovarian cancer and cancer of the
prostate (CaP) [5,6,7,8,9]. Their direct interaction is essential to
support tumor survival and growth [10] by at list three
complementary pathways: (1) An autocrine effect on malignant
cells that produce CCL2, and other CCR2 ligands, and also
express their receptor (CCR2) [10]; (2) Attraction of bone marrow
derived monocytic cells from the bone marrow to target tissues by
chemotaxis, and then inducing their differentiation into macro-
phages [11], in particular tumor associated macrophages (TAMs)
[12,13,14], and (3) pro-angiogenic effects on the endothelium that
also expresses CCR2 [15].
We have recently shown that CCL2 is predominantly expressed
at the human primary tumor site of patients suffering from CaP,
which leads to selective breakdown of immunological tolerance
resulting in a production of anti-CCL2 autoantibodies that are
likely to participate in the regulation of disease [16].
The current study focuses on differentiating the contribution of
CCL2-CCR2 interaction within CCR2+ BM-derived
CD11b+Gr1+ cells from the autocrine effect of CCL2 on CCR2
expressed by the cancer cells. For this purpose we elaborated a
chimera system in which a Luciferase trafected CCR2+ cancer cell
line (TRAMP-C1) is implanted into CCR22/2 mice that were
then reconstituted with BM cells from CCR2+ immunocompetent
mice. The expression of CCR2 displays plasticity during
differentiation of BM monocytic and dendritic cells. A more
stable biomarker for the precursors of these cells is the chemokine
receptor CX3CR1 [17,18,19]. Hence, the current study uses an
adoptive transfer system in which BM CX3CR1+ cells (cx3cr1
gfp)
from CCR2+ mice harboring a targeted replacement of the
CX3CR1gene by an enhanced green fluorescent protein (EGFP)
reporter gene together with the CD45.1 are transferred into
control CCR22/2 mice, to show that these cells, which are
approximately 7% of BM CD11b+ cells, are not only essential for
direct support of the tumor, but also obligatory for the recruitment
of other BMD CD11b+ cells to support tumor development and
angiogenesis.
Finally a soluble CCR2-Ig that selectively neutralizes CCL2
[20] was then used to determine the direct contribution of the
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e28305autocrine interaction of CCL2-CCR2 on the cancer cells to tumor
growth.
Materials and Methods
Animal Models
All animal work was conducted according to the Technion ethic
committee guidlines. C57BL/6 (WT) were purchased from Harlan
(Israel). Breeders of CD45.1+ and CCR22/2 C57BL/6 mice
were purchased from The Jackson Laboratory (Bar Harbor,
Maine). CX3CR1
gfp C57BL/6 mice harboring a targeted
replacement of the cx 3 cr1 gene by an enhanced green fluorescent
protein (EGFP) reporter gene [21], that were generated previously
by one of us (SJ), have been crossed to mice bearing the CD45.1
allotype. All mice were maintained in IVC cages under pathogen-
free conditions. At 6 weeks of age, mice were injected
subcutaneously between the two flanks with 76106 syngeneic
TRAMP-C1 luc. were kindly provided by N. M. Greenberg [22]).
Mice were monitored daily for evidence of illness. Tumor
diameters were measured using a caliper. Tumor volume was
calculated using the formula p/66a6b2, where a is the longest
dimension, and b is the width.
CCR2-Ig soluble receptor
A soluble receptor encoding the E3 domain of CCR2 has been
constructed as we described elsewhereb [20]. This soluble receptor
effectively, and selectively neutralizes the in vivo activities of CCL2
and suppresses experimental autoimmune encephalomyelitis
(EAE) and the growth of human prostate cancer cells in SCID
mice CCR2-Ig [20].
Micro-metastases Detection
Detection of micro-metastases was done according to [23,24].
In a preliminary experiment in which we calibrated the metastatic
tumor model, we observed that under our working conditions, i.v.
injection of 5–7610
6tumor cells/mouse was essential to obtain
clear micro-metastases at the bones and lungs. Due to the high
number of injected cells (76106 C-1.luc cells/mouse) these cells
were administered at a relatively high volume of PBS (400 ml/
mouse) in a protocol that included very slow administration up to
1 min.
Thirty days following reciprocal administration of 7610
6 tumor
cells/mouse (s.c.) to form primary tumor, and the same number of
cells administered i.v. to form micro-metastases tissues from brain,
lungs, heart, liver, bones and the primary tumor sections were
subjected to Luciferase immunohistochemical (IHC) detection,
according [25], as follows: tissues were fixed in 10% buffered
formalin, embedded in paraffin, and sectioned onto glass slides.
Paraffin-embedded sections were hydrated through xylene and
graded alcohol and equilibrated in PBS. Antigen retrieval was
performed by heating the slides in 10 mM sodium citrate (pH 6.0)
at 110uC for 4 min followed by staining for luciferase with
monoclonal mouse anti-luciferase antibody (Clone LUC-1; Sigma)
in a 1:50 dilution. Staining was performed using EnVision Plus
Systems (Dako) according to the manufacturer’s protocol.
Histology, Immunohistochemistry and
Immunofluorescence
Samples were subjected to staining analysis [26] as follows: they
were fixed in 10% formalin in PBS overnight, then dehydrated
and embedded in paraffin. Immunohistochemistry analysis was
performed on serial sections (5 mm) by an immunoperoxidase
technique, using streptavidin-peroxidase and an AEC substrate
chromogen kit (Zymed, San Francisco, CA). Next, tissue samples
were deparaffinized, incubated with 3% H2O2 for 20 min to avoid
endogenous peroxidase activity, and blocked using a non-immune
blocking solution (Zymed) for 20 min. PBS-diluted primary
antibodies were added and incubated overnight. After three
washings, secondary antibody was applied for 1 h, followed by
rinsing with PBS. After peroxidase staining, slides were counter-
stained lightly with hematoxylin. For F4/80+ cells we used a
primary antibody polyclonal rat anti-mouse F4/80(MCA497B,
Serotec, Raleigh, NC), for VEGF detection we used Polyclonal
rabbit anti-VEGF (sc-152, Santa Cruze Biotechnology,) and for
proliferating cells we used Mouse Anti mouse PCNA (MCA1558,
Serotec, NC) [27]. Auto fluorescence staining of necrotic areas was
done as we described in [28]. Anti CD31 staining was conducted
on frozen sections using Rat anti Mouse CD31 mAb (PharMin-
gen,) and FITC-goat anti-mouse IgG(Jackson ImmunoResearch,)
according the protocol we described elsewhere [28].
Imaging of Luciferase Activity In vivo
Imaging was performed using an IVIS200 Imaging System
(Xenogen Biosciences). Mice were anesthetized using isoflurane
and injected intraperitoneally with 150 mg/kg luciferin. Imaging
was done 5 min after the luciferin injection. Quantification of light
from specific regions was done using Living ImageH software
(Xenogen Corporation) and expressed as photons/second.
Bone marrow–derived cell separation
Single-cell suspensions of bone marrow were prepared from the
femurs of heterozygote mutant C57BL/6 mice (CD45
+GFP
+).
Mononuclear cells were isolated using Lympholyte Separation
Medium (Cedarlane Laboratories, Burlington, ON). CD11b+ cells
were positively separated by cell separation kit (MACS beads,
Miltenyi Biotec) and injected (i.v.) into CCR22/2 mice. GFP+
(cx3cr1
gfp) cells were separated using FACSAria Cell-Sorting
System (BD Biosciences, CA).
Statistical analysis
The significance of differences was examined using Student’s t-
test. P values smaller than 0.05 were considered statistically
significant.
Results
CCR22/2 mice display impaired development of CCR2+
primary tumors that become non-metastatic
At the tumor site CCR2 is expressed on invading tumor cells,
the endothelium, and TAMs. In an attempt to study the
distinguishable contribution of non-malignant CCR2+ cells at
the tumor site to tumor development and angiogenesis, wild-type
and CCR22/2 C57BL/6 mice were administrated with 7610
6
CCR2+ TRAMP C1.luc cells that stably over-express a luciferase
reporter gene. On day 65, when tumors reached 500–600 mm
3,
all mice were subjected to CCCD camera analysis, determining
luciferase activity, which represents tumor cell viability and growth
[29]. Figure 1A shows a CCCD camera photography of a
representative control(CCR2+) mouse (a) compared to CCR22/2
mice (b), and analysis of mean total flux (photons per second) of all
six mice within each experimental group (Fig. 1B). These results
show a highly significant difference between both groups
(5.81610
460.7 compared to 1.93610
460.09, p,0.001). Notably,
the decreased luciferase activity in tumors implanted in CCR22/2
mice was not associated with a significant decrease in tumor size, as
measured by caliper (Figure 1C).
We then monitored micro-metastases formation at the brain,
liver, bones and lungs of CCR22/2 and WT mice subjected to
CCR2-CCL2 Contribution to Tumor Growth
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the cellular localization and cell-specific staining for luciferase
activity (relative light units per mg total protein, RLU/mg) of
histological section of organs from all six mice. We could observe
in WT mice an apparent RLU increase in lungs, bones and
primary tumor, all of which were significantly decreased in
CCR22/2 mice (730680 compared to 220630, 440645
compared to 140622, and 16506180 compared to 760680,
p,0.001 for all 3 comparisons).
Taken together, these results show that CCR22/2 mice
display a reduced development of the CCR2+ primary tumor, as
determined by tumor cell viability and spread in various ograns,
but this reduced enzymatic activity was not correlated with the
primary tumor size. Of note, we have not yet ruled out the
possibility that luciferase activity in tumors was reduced due to a
reduction in angiogenesis, a point which we have further
investigated as discussed below.
Impaired development of CCR2+ primary tumor in
CCR22/2 mice is associated with increased necrotic
areas and reduced proliferative response localized within
the central area of the tumor
To explain the discrepancy between the significant reduction in
luciferase activity in primary tumors of CCR22/2 mice
compared to wild type (Figure 1A and 1B), and the comparable
tumor size between these groups, primary tumor sections from all
mice of each group were subjected to histological and immuno-
histochemical analyses. The results in Figure 1E show represen-
tative sections (n=18 per group) of harvested tumors. Auto
fluorescence staining of necrotic areas [28] indicated large necrotic
areas at the primary tumor site developed in CCR22/2 mice,
when compared to wild-type counterparts (Figure 1E, b compared
to a). In addition, PCNA staining for proliferating cells [27]
revealed reduced proliferative responses in tumor sections
obtained from CCR22/2 mice, when compared to their wild-
type counterparts (Figure 1E d compared to c, and f compared to
e). Notably, necrotic areas were localized within the central area of
the tumor where cell proliferation was reduced, and not within the
viable tumor rim. Collectively, these results suggest that reduced
luciferase activity in tumors from CCR22/2 mice (Figure 1)
resulted from impaired tumor proliferation followed by increased
necrosis at the central areas of the tumor.
Impaired development of CCR2+ primary tumor in
CCR22/2 mice is associated with reduced accumulation
of F4/80+ cells, reduced VEGF expression and lack of
angiogenesis
CCL2 is an obligatory mediator in directing the mobilization of
F4/80+ monocytes from the bone marrow via its interaction with
CCR2 [30,31]. Thus CCR22/2 mice are impaired in this
feature, and its consequences [32,33]. Further immuno-histolog-
ical analysis of the sections showed that indeed CCR22/2 mice
had a reduced number of F4/80
+ cells at the tumor site (Figure 1F
b compared to a and d compared to c). It should be noted that of
the CD11b+ BM cells the monocytic cells (F4/80+), but not
granulocytes are CCR2+. This receptor has been shown to be
essential for monocytic exclusive exit from the BM [32], which is
an essential step for their later accumulation at inflammatory/
tumor sites. Here we show that in the absence of CCR2, F4/80+
cells also do not accumulate at the tumor site (Figure 1F).
The development and invasion of a tumor is largely dependent
on its ability to induce angiogenesis, either by producing
angiogenic factors, such as VEGF, in an autocrine manner, or
indirectly via such factors produced by recruited BM cells or
stroma cells at the tumor microenvironment. We therefore
assessed the VEGF-A and CD31 (a marker for endothelial cell)
expression in these tumor sections (Figure 1F) and found a
markedly reduced staining of VEGF-A, that could explain, in part
the significant reduction CD31+ endothelial cells in primary
tumors from CCR22/2 when compared to tumors from WT
mice.Collectively, the above observations suggest that F4/80+
tumor-associated macrophages are essential for sufficient produc-
tion of angiogenic factors, including VEGF, at the tumor site.
Thus their absence leads to impaired angiogenesis resulting in
reduced proliferation and increased necrosis of tumor cells,
particularly at the center of the tumor.
Collectively, the above observations suggest that the lack of both
TAMs and angiogenesis in tumors grown in CCR2/2 mice may
account for the reduced tumor cell viability when compared to
tumors grown in wild-type mice, but could not explain why tumor
size remain similar in both groups.
Bone marrow derived CD11b+CCR2+ cells are essential to
support tumor development and angiogenesis
In an attempt to delineate the role of BM CCR2+ DC/
monocytic cells to tumor development we have conducted two
complementary sets of adoptive transfer experiments. The first
experiment compared the ability of either BM CD11b+ cells from
CCR2+ donors to support tumor development in CCR22/2
mice (Fig. 2), and the other experiment compared the ability of
purified CX3CR1 (GFP+) cells from CCR2+ mice to do so (Fig. 3).
In both experimental systems BM donor CCR2+ cells were
isolated from CD45.1mice harboring a targeted replacement of
the CX3CR1gene by EGFP (cx3cr1
gfp). At first, total CD11b+ cells
were isolated (Fig. 2A 97% purity). Within this CD11b+
population the cx3cr1
gfp cells were as few as 7.2% (Fig. 2A). The
CD11b+ cells from these donors were administered (5610
6/
mouse) one week before the subcutaneous implementation of
7610
6 CCR2+ TRAMP C1.luc cells. On day 65, when tumors
reached a size of 500–600 mm
3, all mice were subjected to CCCD
camera analysis. Fig. 2B shows that the BM cx3cr1
gfp cells from
Figure 1. CCR22/2 mice display impaired development of CCR2+ primary tumors that become non-metastatic. (A) Six CCR2
+/+ C57BL/
6 mice (WT) and six CCR2
2/2 C57BL/6 mice were administered with 7610
6 TRAMP C1-luc cells. Imaging of primary tumor was done on day 60, as
recorded by the CCD camera (IVIS). Panels a & b show representative photos of CCR2
+/+ C57BL/6 mice (WT) (a) and CCR2
2/2 C57BL/6 mice (b) which
were i.p injected with 200 ml luciferin 5 min before the exposure. (B) Computerized CCCD analysis of six mice per group. Results of six mice per group
are shown as total flux (p/s610
4) 6SE. * Indicates p,0.001. (C) Starting day 25, the two groups of mice were monitored for the development of the
primary tumor. Results are shown as tumor volume 6 SE. (D) Micro-metastases luminometer analysis of luc+ counts in organ sections obtained on
day 50 from brain, heart, lungs, bones and primary tumor of CCR2+/+ C57BL/6 mice (WT) and CCR22/2 C57BL/6 mice administrated with 7610
6 C1-
luc cells i.v, and the same number of cells s.c. to form primary tumor. Results are shown as mean relative light units per mg total protein, 9RLU/mg)
6SE. * Indicates p,0.001 (E) Histological and Immunohistochemical analyses of primary tumors from CCR2
+/+ C57BL/6 mice (WT) and CCR2
2/2
C57BL/6 mice. Panels a, b show H&E staining (610) taken by fluorescence microscope, c–f show anti -PCNA staining; c, d (610), e, f (640). (F)
Immunohistochemical and immunofluorescence analysis of primary tumors from CCR2
+/+ C57BL/6 mice (WT) and CCR2
2/2 C57BL/6 mice. Panels a–d
show anti F4/80 staining; a, b (610), c, d (640) , e–h show anti VEGF staining; e, f (610), g, h (640) and i–j show anti CD31 staining (640).
doi:10.1371/journal.pone.0028305.g001
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follows the luciferase activity, (representing tumor cell viability) of
the TRAMP C1.luc cells in representative mice from groups of
either WT or CCR22/2 mice, that were, or were not
reconstituted with the CD11b+ cells from either CCR2+/+ or
CCR22/2 mice. These results represent one of three different
experiments, each with 6 mice per group. In all experiments we
observed that BMcells from CCR2+/+ mice, but not from
CCR22/2 donors could restore tumor growth to comparable
levels that were found in tumors from WT mice. Fig. 2D shows
analysis of the mean total flux (photons per second) of all six mice
within each experimental group showing that the decrease in total
flux observed in CCR22/2 (b compared to a, 1.6360.3610
4
compared to 5.2061.1610
4,p ,0.001) could be fully restored by
BM cells from CCR2 WT but not from BM cells from CCR22/2
mice (d compared to c, 1.760.25 compared to 5.1160.95,
p,0.001).
Histological and immunohistological analyses of representative
sections from each group (18 sections from six mice per group)
show a significant reduction of necrotic areas (auto-fluorescence
staining) in tumors from CCR22/2 mice administered with
CD11b+ cells from CCR2+/+ donors (Figure 2E b compared to c)
accompanied by increased PCNA staining representing prolifer-
ating cells (Figure 2E f compared to e). Furthermore, an increased
VEGF expression (Figure 2E h compared to i) as well as
accumulation of F4/80+ TAMs (Figure 2E k compared to l) were
also observed in tumors from CCR22/2 mice administered with
CD11b+ cells from CCR2+/+ donors. To further assess whether
reduced expression of VEGF (and possibly other proangiogenic
factors) at the tumor site accompanied with reduced formation of
blood vessels, primary tumor sections from all groups were
subjected to immunostaining with anti-CD31 antibodies (a marker
of endothelial cell). Fig. 2E clearly shows a markedly reduced
staining of CD31+ endothelial cells in primary tumors from
CCR22/2 mice when compared to tumors from WT mice
(Figure 2E o compared to m). It should be noted that CD31 is also
expressed on macrophages [34], however Figure 2 clearly show a
marked reduction in staining that well characterizes vessel
structure. These results indicate that the reducedangiogenesis in
such tumors (see also Fig. 1), could be restored following BM
CD11b+CCR2+ cell transplantation (Figure 2E n).
Collectively, these results suggest that BM CD11b+CCR2+ cells
home via CCR2 to the tumor to support its angiogenesis and
subsequent growth by eliciting the production of angiogenic
factors and possibly by other mechanisms, yet to be identified.
Bone marrow derived CX3CR1+ cells are drivers of tumor
angiogenesis
The CX3CR1+ cells (in our system, cx3cr1
gfp) are approximately
7% of CD11b+ BM cells (Fig. 2A). To assess their contribution to
tumor development, we have purified them in two steps. At first,
total CD11b+ BM donor CCR2+ cells were isolated from CD45.1
mice, harboring a targeted replacement of the CX3CR1gene by
EGFP (cx3cr1
gfp). Then GFP+ cells were isolated using FACSAria
Cell-Sorting System (Fig. 3A, 96% purity), and administered
(3610
6/mouse) to CCR22/2 mice bearing a CCR2+ tumor,
under the same experimental conditions as described above
(Fig. 2). Fig. 3B shows the results obtained from representative
mice (CCCD camera) whereas Figure 3C sumerizes the mean total
flux of six mice per group. Together they show that administration
of CX3CR1+GFP cells from CCR2+/+ mice to CCR22/2 mice
barring a CCR2+/+ tumor could fully restore tumor development
in CCR22/2 mice (Fig. 3C, 6.560.5 in WT compared to
1.260.3 in CCR22/2,p ,0.001, and 6.360.6 in BM cells
reconstituted mice). Primary tumor sections were then analyzed by
immunostaining using different chloroforms for CD45.1 (only
transferred cx3cr1
gfp cells) and CD11b+ (Fig. 3D). Analysis of 60
sections from six mice per group (Fig. 3E) revealed that: a. In the
absence of cx3cr1
gfp cells from CCR2+ mice, endogenous CD11b+
cells hardly accumulated at the tumor site (about 20 folds less than
tumors from WT mice) b. Accumulation of endogenous CCR22/2
CD11b+ cells was reconstituted following the administration of
cx3cr1
gfp cells almost to the same levels found in tumors of WT mice
(approximately 85%) to support tumor angiogenesis. Taken
together, our results suggest that BM CCR2+ CX3CR1 cells are
drivers of tumor support not only due to their potential direct
function, but also due to their ability to recruit other CCR22/2
BM cells to the tumor site.
The direct effect of CCL2 on the in vivo development and
progression of the primary tumor
The next approach was to use our experimental system to
delineate the direct contribution of the interaction between the
CCR2+ tumor cells and the CCL2 ligand on tumor growth. The
basic experimental system is identical to the one we used above in
which only the tumor cells expressed CCR2. Here we have added
an additional group in which the CCR22/2 mice that were
implanted with the Luc+ CCR2+ tumor cells (C1-TRAMP) were
subsequently injected (beginning 25 days after tumor injection,
every 5 days, 300 mg/mouse) with a soluble CCR2-Ig receptor
that effectively and selectively neutralizes only CCL2 [20]. In
accordance with the results shown in Figure 1 CCR22/2 mice
bearing CCR2+/+ tumor cells did not differ in tumor size from
control WT mice (Fig. 4A), yet they displayed a significantly
decreased luciferase activity (Figure 4B, C, 7.3161.4 compared
to 1.6960.35, p,0.01). However, the repeated treatment with of
the CCR2-Ig not only further suppressed luciferase activity
(Figure 4B, C, p,0.01), but also led to a significant inhibition in
tumor size (Figure 4A, day 65, 227619 compared to
770665 mm
3,p ,0.001). These results implicate an important
role of CCL2 in supporting tumor development in an autocrine
manner.
Discussion
There is a growing interest in studying the role of BM cells in
tumors, in part due to the presence of ‘accessory’ BM stroma cells
which have been shown to contribute to tumor angiogenesis,
Figure 2. Bone marrow derived CD11b+CCR2+ cells are essential to support tumor development and angiogenesis. (A) CD11b+ BMD cells from
cx3cr1
gfp CCR2+ CD45.1 mice were purified (left panel), analyzed fro the relative mummer of GFP+ cells (right panel) and transferred to CCR22/2
mice bearing CCR2+ tumor (B) shows imaging (IVIS) of a representative mouse as recorded using a GFP filter. (C) Imaging (IVIS) of the primary tumor
on day 60, as recorded by the IVIS camera using – luciferin filter (recording luciferase activity of the cancer cells) as follows: CCR2+/+ C57BL/6 mice
(WT) (a), CCR22/2 mice (b), CCR22/2 transplanted with BM of WT mice(c) and CCR22/2 transplanted with BM of CCR22/2mice. All photos show a
representative mouse per group (1 of 6 mice). (D) The computerized CCCD analysis of six mice per group. Results are shown as total flux (p/s 610
4)
6SE. * Indicates p,0.001 (E) Histological, Immunohistochemical and immunofluorescence analyses of primary tumors from CCR2
+/+ C57BL/6 mice
(WT), CCR2
2/2 C57BL/6 mice and BM transplanted CCR2
2/2 mice. Panel a–c show H&E staining, d–f show anti -PCNA staining, g–i show anti F4/80, j–l
show anti VEGF and m–o show anti CD31.
doi:10.1371/journal.pone.0028305.g002
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PLoS ONE | www.plosone.org 6 January 2012 | Volume 7 | Issue 1 | e28305Figure 3. Bone marrow derived CX3CR1+ cells are drivers of tumor angiogenesis. (A) FACS analysis of cx3cr1
gfp cells purified by FACSAria
Cell-Sorting System from BM of CCR2+ CD45.1 donor mice before their transfer to CCR22/2 mice (B) Imaging (IVIS) of the primary tumor on day 60,
as recorded by the IVIS camera using – luciferin filter (recording luciferase activity of the cancer cells) as follows: CCR2+/+ C57BL/6 mice (WT) (a),
CCR22/2 mice (b), CCR22/2 transplanted with GFP+ cells from BM of CCR2+ donor mice (c). All photos show a representative mouse per group (1
of 6 mice). (C) Computerized CCCD analysis of six mice per group. Results of six mice per group are shown as total flux (p/s 610
4) 6SE. * Indicates
p,0.001. (D) Representative primary tumor sections were then analyzed by to immunostaining using different colors for CD45.1 (red color, only
transferred cx3cr1
gfp cells) and CD11b+ (green). (E) Analysis of 60 sections from six mice per group for the relative number of CD11b+ cells at tumor
sections from each group, and of CD45.1 cells following cell transfer * Indicates p,0.001.
doi:10.1371/journal.pone.0028305.g003
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PLoS ONE | www.plosone.org 7 January 2012 | Volume 7 | Issue 1 | e28305Figure 4. mE3-mIg inhibits the development of primary tumor in CCR2
2/2 mice. (A) Three groups of CCR2
2/2 and one of C57BL/6 mice
were administered 7610
6TRAMP C1-luc cells. 25 days later, mice were repeatedly administered (every 3 days) with 200 mg mE3-Ig, isotype-matched
control mIgG or PBS and monitored for the development of the primary tumor. Results are shown as tumor volume 6 SE. * Indicates p,0.001. (B)
Imaging of the primary tumor was done on day 65, as recorded by the CCD camera(IVIS).Panels a, b & c show representative photos of a CCR2
+/+
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in cases where tumors acquire resistance to antiangiogenic therapy
[35,36,37,38]. Studies using Gr1+/CD11b+ cells have recently
shown to reduce the efficacy of anti-angiogenic therapy neutral-
izing the VEGF-A activity [38]. These cells home to treated tumor
sites and release a number of proangiogenic factors that
compensate on the lack of VEGF [38].
One of the intriguing observations of the current manuscript is
that in the growth kinetics of CCR2+ tumor implanted in
CCR22/2 mice is comparable with the one developed in
CCR2+ mice (Fig. 1C), whereas there is a huge reduction in
illumination as observed by CCCD camera (Fig. 1A, B). Fig. 1E, F
provides some explanation to this discrepancy. It shows, by auto
fluorescence staining, large necrotic areas at the primary tumor
site developed in CCR22/2 mice, when compared to wild-type
mice (Fig. 1E, b compared to a), together with a marked reduction
in F4/80 cell accumulation at this site (Fig. 1F, b compared to a
and d compared to c). Together with the complementary
experiment showing that reconstitution of CCR22/2 mice with
CX3CR1+CCR2+ BM cells from WT mice overcomes the
reduction of fluorescence emission of this tumor (Fig. 3B) our
study implies that in the absence of CCR2+ BM derived cells the
tumor, even though displays growth kinetics that is comparable
with tumors of wild-type mice, yet it undergoes necrosis. This
further emphasizes the role of CCR2+ BM derived cells in tumor
development and survival.
Bone Marrow CD11b+Gr1+ cells, include neutrophils, mono-
cytic cells, and myeloid-derived suppressor cells, all of which are
likely to contribute to tumor angiogenesis [28,38,39,40,41]. Of
these cells, only the monocytic cells and the monocytic derived DC
express CCR2. For these cells the interaction of CCR2+ and its
ligands is essential for directing their mobilization from the BM
[30,31]. Thus CCR22/2 mice are impaired in this feature, and
its consequences as partially revealed by this study [33]. In an
attempt to delineate the contribution of these cells to the
pathogenesis of prostate cancer, we used a chimera system in
which the Luc+ CCR2+ tumor cells (C1-TRAMP) were
administered into CCR22/2 immunocompetent mice, which
subsequently, were, or were not reconstituted with CCR2+
CD11b+ BM cells, or with CCR22/2 CD11b+ BM cells. We
showed that only BM cells from CCR2+ mice could fully restore
tumor development, implicating for the pivotal role of the CCR2+
BM cells in supporting tumor development and angiogenesis
(Fig. 2).
At the tumor site, the vast majority CCR2+ cells are TAMs.
Previous studies have indicated that TAMs display a profound
influence on the regulation of tumor angiogenesis, including
promoting microvessel sprouting (reviewed in [42] and [41]). In a
transgenic mouse mammary tumor model that expresses Polyoma
Middle T antigen (MMTV-PyMT), the depletion of macrophages
led to a marked reduction in vascular density, causing delayed
tumor progression and metastasis. Reintroduction of macrophages
into these mice led to a significant increase in vascular density and
enhanced tumor progression [43]. Very recently Qian et al
elegantly demonstrated the pivotal role of CCL2 in recruiting
TAMS to support breast tumor metastasis [44]. It is likely that
these TAMs are more essential at early stages of tumor
angiogenesis, particularly for tumors that produce limited levels
of angiogenic factors that would be sufficient for their angiogen-
esis. It is intriguing, however, that even BM CCR2+ cells
(macrophages and DC) are only a small portion of BM cells that
home and produce cytokines, chemokines, and angiogenic factors
at the tumor site, and yet their role in such tumors is so essential.
After all, BM CCR2 monocytic cells, neutrophils, and myeloid-
derived suppressor cells also contribute to tumor development and
progression by producing VEGF and other angiogenic factors, and
they are the vast majority of CD11b+ cells that home to the tumor
site. If so, why is the absence of CCR2+ cells so critical for tumor
support? To address this question we have generated an adoptive
transfer system in which purified BM GFP+ cells from CCR2+
mice harboring a targeted replacement of the CX3CR1gene by
EGFP reporter gene (cx3cr1
gfp), together with the CD45.1 congene,
were transplanted into CCR22/2 mice bearing a CCR2+ tumor.
We showed that these cells not only exclusively accumulated at the
tumor site (Fig. 2B), but they were also essential for the recruitment
of other BM cells and therefore are likely to support tumor growth
(Fig. 3).
We therefore suggest a multi-step model in which CCR2+
CD11b+ BM cells accumulate at the tumor site to initially support
tumor development and angiogenesis, resulting in enhanced levels
of various inflammatory cytokines, growth factors and chemokines,
that enable the rapid attraction of other BM cells, including those
that are CCR22, to further assist tumor development and
progression. CCR2 is expressed on two different types of none-
malignant cells at the tumor site: the endothelium [15], and the
TAMs. Our results showing that BM reconstitution of CCR2+
cells in CCR22/2 mice bearing a CCR2+ tumor fully
reconstitutes its development; therefore support the pivotal role
of these receptors on BM cells in supporting tumor angiogenesis.
It is likely that most of contribution of the BM transferred cells
from CCR2+ to CCR22/2 mice resulted from the ability of
CCR2+ monocytic cells to directly support the tumor, and to
recruit other BM cells. Yet, it should be noted, that potentially
some BM cells transferred, could re-differentiate into mature
endothelial cells [45], and by that, they can override the absence of
CCR2 on endothelial cells of the CCR22/2 BM recipient. Using
a direct immunostaining of CCR2 on histological sections from
mice transferred with cx3cr1
gfp cells we could not identify CCR2+
endothelial cells (data not shown).
Our system also enabled determining the direct autocrine effect
of the CCL2-CCR2 autocrine interaction when CCL2 binds its
CCR2 receptor on the tumor cells. Several ligands bind CCR2,
yet CCR2 is likely to be the exclusive target of CCL2. We show
that the administration of CCR2-Ig that selectively neutralize
CCL2 [20] entirely suppress tumor development in CCR22/2
mice, where the only cells that were CCR2+ were the tumor cells
(Fig. 4). This distinguishes, for the first time the autocrine from the
paracrine effect of this key chemokine in the regulation of cancer
diseases.
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with mE3-mIg. Results are shown as total flux (p/s610
4) 6SE. * Indicates p,0.001 when comparing b and c to a, ** Indicates p,0.001 p,0.005 c to
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